ScholarIQanswers from OpenAlex

Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis

PaperCitations, authors & open-access status

Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis have?

ScholarIQcitation count

Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis has 16 citations in the OpenAlex counts ScholarIQ stores.

When was Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis published?

ScholarIQyear

Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis has 2020 year in the ScholarIQ index.

What is the open-access status of Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis?

ScholarIQoa status

Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis has closed oa status in the ScholarIQ index.

What is the DOI of Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis?

ScholarIQdoi

The DOI for Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis is on the source record.

What is the PMID of Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis?

ScholarIQpmid

The PMID for Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis is on the source record.

What is the OpenAlex record for Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis?

ScholarIQopenalex

The OpenAlex for Therapeutic hypothermia in severe hypoxic-ischemic encephalopathy: a cost-effectiveness analysis is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial